Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Rhea-AI Summary

Mirum Pharmaceuticals (Nasdaq: MIRM) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 12th at 10:00 AM EDT.

The company, known for developing therapies for rare and orphan diseases, will provide a presentation accessible via the Investors and Media section on Mirum's corporate website.

For more details, investors can visit the company's site for webcast links and additional information.

Positive

• Participation in a prestigious conference can increase visibility and investor interest.
• Potential to attract new investors and strategic partners through the presentation.

Negative

• No new clinical data or financial updates provided in this announcement.
• Potential investors might find the lack of detailed business updates less compelling.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Wednesday, June 12^th at 10:00 AM EDT.

Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients five years of age and older. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, CHENODAL, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240605867852/en/

Investor Contact:

Andrew McKibben

ir@mirumpharma.com

Media Contact:

Erin Murphy

media@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

When will Mirum Pharmaceuticals present at the Goldman Sachs 45th Annual Global Healthcare Conference?

Mirum Pharmaceuticals will present on June 12th at 10:00 AM EDT.

Where can I find the webcast for Mirum Pharmaceuticals' presentation at the Goldman Sachs 45th Annual Global Healthcare Conference?

The webcast links are available in the Investors and Media section of Mirum's corporate website.

What is the focus of Mirum Pharmaceuticals?

Mirum Pharmaceuticals focuses on developing therapies for rare and orphan diseases.

What is the stock symbol for Mirum Pharmaceuticals?

The stock symbol for Mirum Pharmaceuticals is MIRM.